Position Paper. Reference safety information: challenges to the generic industry due to labelling harmonisation issues among different Member States

Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic

Why is Now the Right Time to Modernise the Eu Variations System?

Medicines Shortages: Causes and Recommendations

AMR Industry Alliance 2020 Progress Report

Medicines for Europe Code of Conduct

OPEN

Perceptions and recommendations of physicians/KOLs on value added medicines

Open

The secret to improve access to value added medicines

OPEN

Biosimilars in the EU – Information guide for healthcare professionals – now available in 23 languages

(PDF/600 KB)

(PDF/1.85 MB)

(PDF/1.82 MB)

(PDF/1.81 MB)

(PDF/1.86 MB)

  • Danish

    (PDF/1.84 MB)

  • Dutch

    (PDF/1.83 MB)

  • Estonian

    (PDF/656.54 KB)

  • Finnish

    (PDF/1.79 MB)

  • French

    (PDF/1.86 MB)

  • German

    (PDF/1.9 MB)

  • Greek

    (PDF/1.84 MB)

  • Hungarian

    (PDF/1.86 MB)

  • Italian

    (PDF/1.85 MB)

  • Latvian

    (PDF/1.8 MB)

  • Lithuanian

    (PDF/1.81 MB)

  • Maltese

    (PDF/710.75 KB)

  • Polish

    (PDF/1.87 MB)

  • Portuguese

    (PDF/1.85 MB)

  • Romanian

    (PDF/1.86 MB)

  • Slovak

    (PDF/1.86 MB)

  • Slovenian

    (PDF/1.86 MB)

  • Spanish

    (PDF/1.84 MB)

  • Swedish

    (PDF/1.84 MB)

Overarching recommendations for improved access to generic and biosimilar medicines in the hospital setting

Medicines For Europe